T1	Disease	14 36	ERCC1 -negative tumors
T2	Pharmacodynamic_phenotype	73 122	response to platinum -based chemotherapy compared
T3	Disease	140 168	ERCC1 -positive tumors , but
T4	Pharmacodynamic_phenotype	188 206	response rates did
T5	Phenotype	250 251	.
R1	increases	Arg1:T1	Arg2:T2
R2	increases	Arg1:T1	Arg2:T3
R3	increases	Arg1:T1	Arg2:T4
R4	increases	Arg1:T1	Arg2:T5
R5	treats	Arg1:T2	Arg2:T1
R6	treats	Arg1:T2	Arg2:T3
R7	isAssociatedWith	Arg1:T2	Arg2:T4
R8	treats	Arg1:T3	Arg2:T1
R9	influences	Arg1:T3	Arg2:T2
R10	influences	Arg1:T3	Arg2:T4
R11	influences	Arg1:T3	Arg2:T5
R12	treats	Arg1:T4	Arg2:T1
R13	increases	Arg1:T4	Arg2:T2
R14	influences	Arg1:T4	Arg2:T3
R15	influences	Arg1:T4	Arg2:T5
R16	isAssociatedWith	Arg1:T5	Arg2:T1
R17	isAssociatedWith	Arg1:T5	Arg2:T2
R18	isAssociatedWith	Arg1:T5	Arg2:T3
R19	isAssociatedWith	Arg1:T5	Arg2:T4
